NCT05254899 2022-02-24
Anti-PD-1 Antibody and P-GEMOX Chemotherapy Combined With Radiotherapy in High-risk Early-Stage ENKTL
ChineseAMS
Phase 2 Unknown
Clinical Trials
7 trialsNCT05149170 2021-12-08
Radiotherapy and Anti-PD-1 in Low-risk ES-ENKTCL
ChineseAMS
Phase 2 Unknown
NCT04994626 2021-08-06
Ibrutinib Combined With Rituximab for Treatment of Relapsed Refractory MYD88 and CD79A/B (or CD79B Alone) DLBCL Who Have Received at Least Two Prior Therapies
ChineseAMS
Phase 2 Unknown
NCT04425824 2020-06-16
Toripalimab Combine With Rituximab for Treatment of Relapsed Refractory CD20 Positive Diffuse Large B-cell Lymphoma
ChineseAMS
Phase 2 Unknown
NCT02560441 2018-01-03
Trial of IPGDP Regimen Chemotherapy in Patients With Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type
ChineseAMS
Phase 2 Unknown
NCT02276248 2017-08-16
Radiotherapy Combined With GDP Chemotherapy in Stage I/II Extranodal Natural Killer/T-cell Lymphoma
ChineseAMS
Phase 2 Completed
NCT02404571 2016-07-26
GDP in Frontline Chemotherapy for Patients With PTCL-NOS
ChineseAMS
Phase 2 Unknown